Residual cancer cells after apparent complete pathological response to neoadjuvant therapy in oesophageal adenocarcinoma
Br J Surg
.
2024 Apr 3;111(4):znae103.
doi: 10.1093/bjs/znae103.
Authors
Robert C Walker
1
,
Jack Harrington
1
,
Stella P Breininger
1
,
Oliver Pickering
1
,
Samuel L Hill
1
,
Benjamin P Sharpe
1
,
Ben Grace
1
,
Ian Reddin
1
,
Rushda Rajak
2
,
Antigoni Manousopoulou
3
,
Spiros D Garbis
3
,
Zoë S Walters
1
,
Matthew J J Rose-Zerilli
1
,
Timothy J Underwood
1
Affiliations
1
School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
2
Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
3
Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasedena, California, USA.
PMID:
38630793
PMCID:
PMC11023542
DOI:
10.1093/bjs/znae103
No abstract available
MeSH terms
Adenocarcinoma* / pathology
Esophageal Neoplasms* / therapy
Humans
Neoadjuvant Therapy
Neoplasm, Residual
Supplementary concepts
Adenocarcinoma Of Esophagus
Grants and funding
Royal College of Surgeons of England
A23924/Cancer Research UK Advanced Clinician Scientist Fellowship
2016/JGF/0003/John Goldman Fellowship
Southampton CRUK Centre Development Fund